Endonovo Therapeutics Inc. ENDV Archives - Page 3 of 5

WednesdaySep 18, 2019 2:17 pm

QualityStocksNewsBreaks – HTC Extraction Systems (TSX.V: HTC) Securing Several Hemp Biomass Tolling Contracts

HTC Extraction Systems (TSX.V: HTC), a gas, liquids and biomass extractor and refiner, recently entered into a tolling agreement to process five million kilograms of hemp biomass. An article discussing the company reads, “HTC recently announced its entry into a hemp-biomass tolling agreement, which will involve the processing of hemp biomass for the 2019 crop year (http://ibn.fm/hjw4g). The agreement covers 4,200–5,000 acres of hemp in Saskatchewan, utilizing five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process an estimated five million kilograms of hemp biomass to extract CBD full-spectrum oil (FSO). The company will be paid a…

WednesdaySep 18, 2019 2:11 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Developing Solutions to Meet Major Therapeutic Needs

Endonovo Therapeutics (OTCQB: ENDV) develops, manufactures and distributes innovative medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. An article discussing the company reads, “Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical® Therapy represents ‘a fascinating new frontier.’ Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. . . . ‘Endonovo has assembled a pipeline that…

MondaySep 09, 2019 1:08 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Enters Partnership with Veterans Healthcare Supply Solutions, Appoints Dr. Samir Awad to Scientific Board

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announced a partnership with Veterans Healthcare Supply Solutions to initiate SofPulse® sales to Veterans Health Administration and military hospitals. In addition, Endonovo announced its appointment of Dr. Samir Awad to its scientific advisory board. “This partnership with Veterans Healthcare Supply Solutions and the appointment of Dr. Samir Awad to our scientific advisory board are major accomplishments for our young company,” Endonovo CEO Alan Collier stated in the news release. “VHSS is a true leader and provides an efficient procurement platform for today’s federal government buying agencies. When…

FridaySep 06, 2019 2:32 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Planning Nationwide Rollout of Pain-Management Device

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, plans to have its innovative pain-management device available in all 50 states by 2020. An article discussing the company reads, “Technological advancements in the field will also contribute to the market’s growth by enabling the development of more effective devices. There are multiple types of pain-management devices. The market is currently dominated by neurostimulation devices, which accounted for over 50% of the sector’s revenue generated in 2018. This segment is anticipated to maintain its industry dominance over the forecast period. . . . Recently, Endonovo announced the rollout…

FridayAug 30, 2019 12:03 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Appoints New Member to Scientific Advisory Board

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, this morning announced the appointment of orthopedic surgeon Dr. Geoffrey Abrams to its scientific advisory board. Dr. Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine as well as the director of sports medicine for Stanford’s varsity athletes. “We are thrilled to announce that Dr. Abrams is joining the Endonovo family by serving on the scientific advisory board. His participation will be instrumental as we continue to introduce the SofPulse® technology to post-surgical care to fight the opioid epidemic,” Endonovo CEO Alan…

ThursdayAug 29, 2019 12:06 pm

Endonovo Therapeutics Inc. (ENDV) Promotes Alternative to Opioid Addiction with Non-Narcotic Wearable Medical Device for Post-Op Pain

More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018 Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving as a contributing factor to impaired driving-related fatalities The average rate of later opioid dependence and addiction among surgical patients hovered at 12 percent Four out of five heroin users first misused prescription opioids, while 11.5 million people misused opioids in 2016 Endonovo’s SofPulse(R) is clinically proven to significantly speed recovery following surgery,…

WednesdayAug 28, 2019 3:02 pm

Global Pain Management Device Market Growing Rapidly, Endonovo Therapeutics Inc. (ENDV) Works on National Rollout of Innovative Solution

A rapidly aging population and technological advances are contributing to the fast growth of the global pain management device market The market is currently dominated by neurostimulation devices, which accounted for half the revenue reported in 2018 – a trend that’s likely to continue over the next few years Endonovo Therapeutics is already establishing a leading position in the niche; the company’s SofPulse(R) pain management device has been rolled out in a national network of hospitals, clinics and pain management centers for thorough evaluation The global pain management device market is anticipated to grow rapidly through 2026, expanding at a…

WednesdayAug 14, 2019 9:22 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Posts Q2 2019 Financial Results

Endonovo Therapeutics (OTCQB: ENDV) on Tuesday posted the company’s financial and operating results for the second quarter. The company reported revenues for the three months ended June 30, 2019 of $62,729, a sharp increase compared to $12,854 for the same period last year. Gross profits for the second quarter were $33,156, as compared to $12,304 for the same period last year. Endonovo also provided an update on the PEMF assets it acquired from Rio Grande Neurosciences for $4.5 million in December 2017. “I am pleased to announce we have executed the business plan and strategy we implemented after acquiring the…

FridayAug 02, 2019 1:15 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Positioning SofPulse as Natural Post-Surgical Alternative to Opioids

Endonovo Therapeutics (OTCQB: ENDV) is a developer of safe, wearable and non-invasive medical devices. The company’s SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. An article discussing the company reads, “SofPulse was recently rolled out in hospitals, nursing centers and wound care centers throughout the U.S. as an effective, postsurgical opioid alternative. As per an official Endonovo announcement, the company plans to be in the evaluation stage with 600 hospitals within the coming 18 months (http://ibn.fm/7L5G6). In addition, Endonovo will distribute SofPulse therapy devices to Veterans Administration facilities and Department of Defense health-care facilities. .…

TuesdayJul 23, 2019 2:00 pm

QualityStocksNewsBreaks – Endonovo Therapeutics Inc.’s (ENDV) SofPulse Safely Reduces Pain, Swelling

Endonovo Therapeutics (OTCQB: ENDV) is a commercial-stage developer of noninvasive Electroceutical(TM) Therapeutic devices that target patient pain and inflammation while supporting wound recovery. An article discussing the company reads, “Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse(R) is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving the patient’s natural recovery experience (http://ibn.fm/qHmMQ). . . . The efficacy of SofPulse targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue, is well documented and supported by peer-reviewed clinical research. Among the…

Site Search

Company Search

Tag: Endonovo Therapeutics Inc. ENDV